1. Home
  2. TOP vs SNTI Comparison

TOP vs SNTI Comparison

Compare TOP & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$2.23

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.41

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
SNTI
Founded
2015
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
31.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TOP
SNTI
Price
$2.23
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
434.5K
292.5K
Earning Date
01-20-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
81.25
77.31
EPS
N/A
N/A
Revenue
$4,723,765.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
41.89
N/A
52 Week Low
$0.61
$0.42
52 Week High
$3.33
$2.88

Technical Indicators

Market Signals
Indicator
TOP
SNTI
Relative Strength Index (RSI) 55.79 21.66
Support Level $0.89 N/A
Resistance Level $2.88 $1.02
Average True Range (ATR) 0.33 0.09
MACD -0.03 -0.05
Stochastic Oscillator 40.16 0.97

Price Performance

Historical Comparison
TOP
SNTI

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: